Sterify Gel (mucoadhesive bioactive gel)

PreclinicalSmall molecule

Sterify Gel (mucoadhesive bioactive gel) is one of 8 small molecule programs targeting Peri-Implantitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peri-ImplantitisActive, not recruiting

Peri-ImplantitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Peri-Implantitis

#DrugCompanyPhaseTrials

Minocin

Peridex

1 3

Azithromcyin

BBin Cao

Approved

1 4

Peridex

DDexcel Pharma Technologies Ltd.

Phase 2

1 5

Minocycline Hcl

OOraPharma

Phase 3

2 6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

2 7

Flagyl

DDePuy Orthopaedics

Preclinical

2 8

Sterify Gel (mucoadhesive bioactive gel)

UUniversity of Pavia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Peri-Implantitis

NCT07088679

Clinical

Trials by Indication[1]

Peri-Implantitis1 trial

Efficacy of a Natural Bioactive Gel as an Adjunct to Standard Therapy in the Treatment of Peri-Implantitis: A Randomized Controlled Split-Mouth Clinical Trial

Recruiting·UUniversity of Pavia·Preclinical·NCT07088679·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sterify Gel (mucoadhesive bioactive gel). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sterify Gel (mucoadhesive bioactive gel) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sterify Gel (mucoadhesive bioactive gel). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pavia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Pavia

Sterify Gel (mucoadhesive bioactive gel)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Peri-Implantitis1 trial

References

Drug Info

Quick Facts

Related News